1-2 of 2
Evgeny Degtyarev
Close
Sort by
Journal Articles

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Michael R. Bishop, Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, Anna Sureda, Richard Greil, Catherine Thieblemont, Franck Morschhauser, Martin Janz, Ian W. Flinn, Werner Rabitsch, Yok Lam Kwong, Marie José Kersten, Monique C. Minnema, Harald Holte, Esther Hian Li Chan, Joaquin Martinez-Lopez, Antonia MS Mueller, Richard T. Maziarz, Joseph P. McGuirk, Emmanuel Bachy, Steven Le Gouill, Martin Dreyling, Hideo Harigae, David A. Bond, Charalambos Andreadis, Peter A. McSweeney, Mohamed A. Kharfan-Dabaja, Simon Newsome, Evgeny Degtyarev, Chris Del Corral, Giovanna Andreola, Aisha Masood, Stephen J Schuster, Ulrich Jaeger, Peter Borchmann, Jason R. Westin
Journal: Blood
Blood (2021) 138 (Supplement 2): LBA-6.
https://doi.org/10.1182/blood-2021-155068
Published: 2021
Journal Articles

Comparison of Clinical Outcomes Among Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel in the Elara Trial Versus a Real-World External Control Arm of Patients Treated with Standard of Care

Yanni Hao, Wei-Chun Hsu, Craig S Parzynski, C Lobetti Bodoni, Evgeny Degtyarev, Lisa Hampson, Aisha Masood, Wen-Hsing Wu
Journal: Blood
Blood (2021) 138 (Supplement 1): 2419.
https://doi.org/10.1182/blood-2021-147781
Published: 2021